Posttransplant lymphoproliferative disorders (PTLDs) occur in approximately 2% of solid organ or bone marrow transplant recipients and are often associated with Epstein-Barr virus (EBV) infection. Their successful treatment may require chemotherapeutic regimens, although reduction of immunosuppression sometimes suffices. 1, 2 PTLDs arise in the setting of immune dysregulation, and tumor-infiltrating T cells, including regulatory T cells (Tregs), have been shown to correlate with outcome in these disorders, as well as in similar, de novo occurring lymphomas such as diffuse large B-cell lymphoma (DLBCL). 3, 4 The recent US Food and Drug Administration approval of the anti-CD30 monoclonal antibody brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma (cHL) and anaplastic large cell lymphoma 5, 6 has raised the possibility of effectiveness of the drug in other CD30+ lymphomas (including PTLDs) 7, 8 and has led to inquiries regarding the CD30 expression status of a wide variety of lymphomas. PTLDs are known to express CD30, but few studies have formally studied expression in relation to tumor and patient characteristics. 1, 9, 10 Aside from the relevance to treatment with brentuximab, CD30 expression is a favorable prognostic marker in de novo DLBCL 11, 12 and monomorphic PTLD, including DLBCL. 9 Monomorphic PTLD-DLBCLs much more frequently express CD30 (73% 9 ) compared with de novo DLBCL (up to 38%
The correlation of CD30 expression with favorable outcomes in both de novo DLBCL and monomorphic PTLD-DLBCL raises the possibility of a role for this antigen in mediating more favorable pathophysiology. CD30 is a tumor necrosis factor (TNF) family receptor with diverse and opposing actions depending on which costimulatory signals are present. 14, 15 While the role of CD30 in the lymphoma microenvironment is poorly characterized, CD30 interaction with CD30 ligand (CD30L) could promote neoplasia via mechanisms described in its normal physiology, including upregulation of cell proliferation/ survival and downregulation of the immune response. 16, 17 On the other hand, CD30-CD30L interaction could also suppress neoplasia, given that it upregulates susceptibility to apoptotic signaling and is required for expansion of Tregs and Treg suppressor function under normal conditions. 18, 19 Treg infiltration itself has been shown to predict a more favorable outcome in some lymphomas, such as follicular lymphoma and DLBCL, but not in PTLD. 3, 4, 20 Despite a higher frequency of expression of CD30 compared with de novo DLBCL, studies have shown that monomorphic PTLD-DLBCLs demonstrate an order of magnitude less infiltration of Tregs. 3, 4 The different tumor and host phenotypes found in iatrogenically immunosuppressed patients with PTLD suggest an alternative pathophysiology compared with de novo DLBCL in immunocompetent patients.
To date, CD30 expression and Treg infiltration have not been studied simultaneously in any PTLDs or in de novo DLBCL. To further explore the seemingly unique tumor and host phenotype of monomorphic PTLD-DLBCL, we studied CD30 expression and Treg infiltration (as defined by FoxP3 positivity) in PTLDs and correlated with clinicopathologic features. We also compared our findings with previous reports of tumor CD30 and host Tregs in PTLDs and de novo DLBCL to further investigate the relationship of CD30 expression and Treg infiltration in PTLD.
Materials and Methods

Patients
We searched the pathology archives of the Medical College of Wisconsin to identify cases diagnosed as PTLD between January 1994 and December 2014. In total, 148 previously characterized de novo DLBCLs served as controls. All cases were reviewed and the diagnosis was confirmed by at least one of three board-certified hematopathologists (H.O., S.K., and A.H.). Cases were classified according to the 2016 World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. 21 Five cases without adequate formalin-fixed, paraffin-embedded (FFPE) tissue were excluded. Clinical information was collected from the electronic medical record and included age at diagnosis, sex, anatomic site of PTLD presentation, transplant type, and follow-up (alive vs dead). Overall survival (OS) was calculated from the day of PTLD diagnosis to either death or the last known follow-up. This study received institutional review board approval from the Medical College of Wisconsin. Any CD30 expression in tumor cells was defined as positive. CD30 positivity was further classified by percentage of tumor cell staining, in quartiles (<25%, 25%-50%, 50%-75%, and >75%). Total T cells were enumerated by CD3 positivity and T regulatory cells were by FoxP3 nuclear positivity (see below). The Hans criteria 22 were used to establish cell of origin phenotype in the subset of 22 PTLD-DLBCL cases. EBV status was determined by in situ hybridization (Dako). Cases were considered positive when Epstein-Barr encoding region (EBER) was expressed in lymphoma cells beyond the occasional rare positive small B cells typically seen in immunocompetent patients with prior exposure to EBV infection.
Immunohistochemistry
Data Analysis
CD3 and FoxP3 T-cell counts were performed at ×400 total magnification using a Miller disc. Positive cells within the grid were counted. In cases where manual counts for the entire grid area were not feasible (as with CD3 staining), the number of cells within the grid were calculated/estimated by multiplying the number of cells intersected by the outer grid lines on perpendicular axis. Ten intratumoral high-power fields (hpfs) were counted with data reported as a range, mean, and median per hpf. 
Statistical Analysis
Statistical analyses were carried out in GraphPad Prism, version 5.0b (GraphPad Software, San Diego, CA). Variables between groups were compared by Fisher's exact and nonparametric Mann-Whitney tests; a P value less than .05 was considered statistically significant.
Results
Patient Characteristics
A total of 33 cases of PTLD with adequate tissue were identified. Diagnoses consisted mostly of monomorphic PTLDs (n = 24, 73%), followed by seven (21%) polymorphic PTLDs and two (6%) cHL-type PTLDs.
Of the monomorphic PTLDs, two were further classified as Burkitt lymphoma (BL) and 22 as DLBCL. No early lesions or T/natural killer-cell PTLDs were represented in this series. The clinicopathologic features are presented according to status of CD30 expression in ❚Table 1❚. The median age of the patients at PTLD diagnosis was 48 years, with a range of 20 to 77 years. The male to female ratio was 2.3:1. Transplant types included 25 solid organ transplants (11 kidney, six liver, three lung, three multiorgan, and two heart) and eight bone marrow transplants. Most PTLDs (19/31, 61%) presented greater than 1 year after transplant, with a median time from transplant to PTLD diagnosis of 45 months (range, 1-168 months). Primary extranodal disease was common; anatomic sites of the PTLDs included 18 based in lymphoid tissue (lymph node, spleen, or tonsil) with or without additional organ involvement and 15 at extranodal sites (seven in the gastrointestinal tract, five in the lung, and three in the central nervous system). On H&E-stained slides, necrosis was noted in 26 (79%) of 33 cases. By EBER in situ hybridization, 25 (76%) of 33 cases were positive for EBV. At the time of this retrospective review (median follow-up, 55 months; range, 1-188 months), 22 patients were alive, eight were deceased, and three were lost to follow-up with no known mortality. The deceased patients had a median time from PTLD diagnosis to death of 50 months (range, 1-75 months). Of the 22 living patients with follow-up information available, the median time from diagnosis to last follow-up was 55 months (range, 14-188 months).
The 5-year OS for monomorphic PTLDs was 71%.
CD30 Expression in PTLD Cases
CD30 expression was positive in 26 (79%) of 33 PTLDs and 17 (77%) of 22 monomorphic PTLD-DLBCLs ❚Table 2❚ and ❚Table 3❚. CD30+ cases showed the following staining patterns: nine (34%) of 26 were greater than 75%, two (8%) of 26 were 50% to 75%, two (8%) of 26 were 25% to 50%, and 13 (50%) of 26 were less than 25% ❚Image 1❚. All polymorphic PTLDs were positive for CD30 (7/7), and both cHL PTLDs were positive for CD30 with 100% of tumor cells staining. Both BL PTLDs were negative for CD30, with no tumor cells staining. Of the 22 monomorphic PTLD-DLBCLs, 17 (77%) were CD30+ compared with 56 (38%) of 148 de novo DLBCLs (P = .009), as we previously reported. 13 Four (17%) of 22 monomorphic PTLD-DLBCLs showed CD30 expression in less than 1% of lymphoma cells, with a median of 28% CD30+ cells in the monomorphic PTLD-DLBCL group. EBV positivity was also more common in the CD30+ PTLDs compared with CD30-cases: 85% vs 43%, P = .042. The 5-year OS was similar for CD30+ and CD30-PTLDs: 73% vs 71%, P = .957, and there were no other statistically significant differences, including age, sex, time from transplant to PTLD diagnosis, bone marrow vs solid organ transplant, anatomic site, monomorphic vs polymorphic PTLD, and Values are presented as number/total number (%) unless otherwise indicated.
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CD30 Expression, Cell of Origin, and EBV Status in Monomorphic PTLD-DLBCL Cases
Of the 22 monomorphic PTLD-DLBCLs, 14 (64%) were subtyped as non-germinal center (GC) cell of origin and eight (36%) as GC type. Thirteen (93%) of 14 non-GC-type monomorphic PTLD-DLBCLs were CD30+ compared with four (50%) of eight of the GC type (P = .039) ( Table 3 ). The 5-year OS was similar for CD30+ and CD30-monomorphic PTLD-DLBCLs: 69% vs 60%, P = .920. Although the 5-year OS was longer in GC-type monomorphic PTLD-DLBCLs compared with non-GC cases, the difference did not reach statistical significance: 88% vs 31%, P = .151. However, the time from transplant to PTLD diagnosis was significantly longer in GC-type monomorphic PTLD-DLBCLs than in non-GC cases: 104 vs 18 months, P = .009. PTLD-DLBCLs were EBER+ in 15 (68%) of 22 cases, and the proportion of positive cases was significantly higher in CD30+ tumors compared with CD30-PTLD-DLBCLs: 82% vs 20%, P = .021 (Table 3 ). The 5-year OS was similar for EBV+ and EBV-PTLD-DLBCLs: 62% vs 71%, P = .905.
Treg Infiltration in PTLD Cases
In the 29 of 33 cases studied for CD3 and FoxP3 by IHC ❚Image 2❚, the median CD3+ T-cell and FoxP3+ Treg counts/hpf were 96 (range, 9-509) and 1.0 (range, 0-33.5), respectively. Median FoxP3 counts were similar in monomorphic: 1.0 (range, 0-33.5) and polymorphic PTLDs: 0 (range, 0-27) (P = .993). FoxP3 content was highest in the setting of heart transplant (median, 17.3; range, 1-33.5) and lowest in the setting of bone marrow transplant ❚Image 2❚ (A) H&E, (B) CD3 immunohistochemistry, and (C) FoxP3 immunohistochemistry (all at ×400) in a CD30+, EBV+ monomorphic posttransplant lymphoproliferative disorder-diffuse large B-cell lymphoma.
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AJCP / Original article (median, 0; range, 0-24), although this difference was not statistically significant (P = .356). The median CD3+ T-cell and FoxP3+ Treg count/hpf was higher in CD30+ than in CD30-PTLDs, 101 vs 50 (P = .009) and 3 vs 0 (P = .012), respectively ( Table 2) . We found a higher number of infiltrating FoxP3+ Tregs in patients who were alive at the latest follow-up compared with those who had died: median of 10 vs 0 per hpf; however, this difference was not significant (P = .160).
FoxP3 and T-cell subset data for the 22 PTLDDLBCLs are summarized in Table 3 . The median CD3+ T-cell and FoxP3+ Treg count/hpf was higher in CD30+ than in CD30-PTLD-DLBCLs, 102 vs 35 (P = .008) and 8 vs 0 (P = .016), respectively. The median number of infiltrating FoxP3+ Tregs/hpf was also higher in patients with PTLD-DLBCL who were alive at the latest follow-up compared with those who had died, although not statistically significant: 14.3 vs 0.5 (P = .162).
Discussion
We confirm a previous report that CD30 is expressed in most PTLDs, with an overall positivity of 76%. Vase et al 9 is the only group to date to specifically study CD30 in PTLDs and found expression by IHC in all types of PTLD, including monomorphic PTLDs. In their study, 85.25% of cases were positive, with a cutoff of 20% established via a combined digital and manual quantification of staining. 9 In contrast to the report by Vase et al, 9 we used a semiquantitative manual assessment by a single hematopathologist but counted any proportion of cells staining as positive for CD30. Of 26 CD30+ cases, 13 showed expression in more than 25% of cells. The difference in the lower percentage of staining in PTLDs from our cohort compared with the prior study may be attributed to the difference in IHC methods or to a higher sensitivity of their combined manual and digital method in quantifying CD30 staining. Of note, while the CD30 expression data are presented in binary fashion (positive/negative) as well as divided into quartiles, analyzing CD30 expression as a categorical (as opposed to binary) variable did not affect the statistical significance of our finding.
Most PTLD cases expressing CD30 raise the possibility of effective anti-CD30 therapy with brentuximab vedotin. 23 Promising results include case reports such as the complete remission of a CD30 + monomorphic PTLD-DLBCL with single-agent treatment with brentuximab. 8 Judging by our cohort, most our patients with PTLD, including the PTLD-DLBCL cases, would be eligible for anti-CD30 therapy, perhaps in relapsed/refractory lymphomas, as seen in cHL and anaplastic large cell lymphoma. Literature data indicate that the percentage of CD30+ cells does not necessarily correlate with response to treatment, as several patients with little to no CD30 by visual IHC inspection achieved a complete remission in a phase II study. 24 However, computer-assisted digital image analysis showed that most of these DLBCL responders had 1% or less CD30 expression, and correlative analyses demonstrated that 1% or less CD30 expression resulted in a trend toward a higher response rate and significantly longer median OS. As such, a higher proportion of CD30+ tumor cells may correlate with a higher response rate to brentuximab therapy.
Recently, CD30 expression has been used to define a subgroup of de novo DLBCL (14% of cases) with a favorable prognosis.
11 CD30 positivity is also correlated with a more favorable outcome in PTLD. 9 In their study, Vase et al 9 also noted that for CD30+ PTLD-DLBCL, better outcomes were noted regardless of EBV status, and this held significance in multivariate analysis. We have previously examined CD30 expression by IHC in a large series of de novo DLBCLs and revealed positivity in 56 (38%) of 148 cases, using the same criteria for CD30 expression as in the current PTLD cohort. 13 Even with this higher proportion of CD30+ DLBCLs compared with prior reports, the difference in CD30 positivity between monomorphic PTLD-DLBCLs and de novo DLBCLs is statistically significant (P = .009). Unlike the PTLD study by Vase et al, 9 we did not find a more favorable outcome in CD30+ cases, as the 5-year OS was similar to that of CD30-cases. However, we did find a significant difference in CD30 expression between EBV+ and EBV-cases (P = .042). Most of the PTLDs (76%) were positive for EBV by EBER in situ hybridization. EBV is a known inducer of CD30 expression on B cells in vivo, 25 but the relationship between EBV and CD30 expression in tumor cells remains poorly described. From a pathophysiologic standpoint, CD30 is capable of promoting the activation of nuclear factor-κB via interaction with TNF-associated factors (TRAFs). At the same time, EBV is also known to interact with TRAFs through its LMP1 antigen, thus providing a potential link between CD30 expression and EBV-driven lymphomagenesis. 15, 26, 27 Other studies have shown that increased serum levels of soluble CD30 protein may have predictive value for events such as EBV infection in immunocompetent individuals or graft failure in solid organ transplant recipients. 10, 28 These data may suggest that CD30-mediated immune activation elicits a more vigorous antitumor response and potentially explains the favorable effect of CD30 expression in PTLD. Among EBV+ PTLDs, Vase et al 9 reported a protective effect of CD30 expression. However, CD30 expression was associated with a favorable outcome regardless of EBV status in their cohort of monomorphic PTLD-DLBCLs.
As a further comparison of de novo DLBCLs and monomorphic PTLD-DLBCL, we examined the cell of origin and confirmed the findings of Vase et al 9 that CD30 positivity correlates with a non-GC phenotype (P = .039). We also confirm that among CD30+ GC phenotype cases, expression tends to be lower, with all of our cases showing less than 25% CD30 staining, although this fact was perhaps better captured by their quantitative method. The report by Hu et al 11 of CD30 in de novo DLBCL did not find any significant difference in CD30 expression between GC and non-GC subtypes and actually found that a nonsignificantly greater number of GC-type DLBCLs expressed CD30 (59% vs 41%, P = .164). We also find that the time from transplant to PTLD diagnosis is significantly longer in GC vs non-GC monomorphic PTLD-DLBCL cases. Since the 5-year OS was not statistically different in GC vs non-GC monomorphic PTLD-DLBCL cases, the results from our study and the one by Vase et al 9 indicate that, unlike in de novo DLBCL, the cell of origin may not have a prognostic impact in PTLD-derived DLBCLs.
We explored the seemingly unique posttransplant CD30+ phenotype of monomorphic PTLD-DLBCL compared with de novo DLBCL by studying Treg infiltration. Given that CD30 normally induces proliferation of Tregs and promotes their suppressor function, we expected to find greater Treg infiltration in CD30+ vs CD30-PTLD. We found a statistically significant positive correlation with PTLD CD30 expression and median Treg infiltration (P = .01), and this correlation held true in the PTLD-DLBCL subset, as well. We saw a similar difference in the total number of infiltrating T cells between CD30+ and CD30-cases, which may indicate that the difference in FoxP3+ Tregs is simply a reflection of the differential number of T cells. However, we argue against this potential explanation by pointing out that the ratio of CD3/FoxP3 T cells is not proportional between CD30+ and CD30-PTLDs. To our knowledge, our study is the first to explore CD30 positivity and Tregs in PTLDs, and these novel data suggest a pathophysiologic link between CD30 expression and Treg infiltration.
When compiling data from previous separate reports by other authors, using nearly identical counting methods per hpf, de novo DLBCL exhibits a median order of magnitude higher infiltration of Tregs compared with PTLD-DLBCL (140.5 vs 1.7). 3, 4 We confirm the report of Richendollar et al, 3 which reported a median PTLD Treg infiltrate of 1.2 per hpf. We propose that the lesser Treg infiltration in PTLDs corresponds to a preserved but less intense immune response in the posttransplant setting compared with de novo DLBCLs occurring in immunocompetent individuals. The greater infiltration of T cells and Tregs in CD30+ monomorphic PTLDDLBCLs suggests that CD30 may be responsible for a better preserved, albeit still diminished, immune response to the tumor, which may partially account for the better prognosis noted in this subgroup of PTLDs in prior studies. 9 One of the limitations of our study is that the patients were accrued over a long period, with variations in immunosuppressive regimens and/or lymphoma therapies used. The high proportion of patients still alive (22 of 33) and the incomplete follow-up data in a subset of cases also limit our ability to assess long-term outcomes. Larger studies aggregating more PTLD cases and longer follow-up times with detailed treatment data might better address the prognostic significance of CD30 expression in PTLDs.
In summary, we confirm that most PTLDs express CD30, and we report the novel finding that significantly more Treg infiltration is present in CD30+ PTLDs. We define a distinct phenotype of monomorphic PTLD-DLBCL compared with de novo DLBCL, with significantly higher frequency of CD30 expression and non-GC cell phenotype. To our knowledge, this is the first study to compare CD30 expression of de novo DLBCL and monomorphic PTLD-DLBCL. Our findings, combined with the few other studies addressing CD30 in these two tumors, suggest differential expression of CD30 in B-cell lymphomas arising in the setting of immune dysregulation.
